A proof-of-concept trial revealed that GA2, a second-generation vaccine candidate that uses genetically attenuated malaria parasites, prevented 89% of participants who received it from being infected with malaria.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.